Mirae Asset Global Investments
PYXS icon

Mirae Asset Global Investments’s Pyxis Oncology PYXS Stock Holding History

Mirae Asset Global Investments’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.53K Sell
2,833
-415
-13% -$794 ﹤0.01% 1586
2026
Q1 		$4.74K Buy
3,248
+222
+7% +$335 ﹤0.01% 1529
2025
Q4 		$3.48K Buy
3,026
+628
+26% +$2.21K ﹤0.01% 1633
2025
Q3 		$5.32K Buy
2,398
+5
+0.2% +$7 ﹤0.01% 1612
2025
Q2 		$2.63K Buy
2,393
+403
+20% +$454 ﹤0.01% 1560
2025
Q1 		$2.11K Buy
1,990
+8
+0.4% +$11 ﹤0.01% 1536
2024
Q4 		$3.15K Buy
+1,982
New +$5.72K ﹤0.01% 1574

Other funds holding PYXS

HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
HIMS
Hager Investment Management Services New London, New Hampshire $217M AUM 56.89% 1-Year Est. Return
FUBT
First United Bank & Trust Oakland, Maryland $348M AUM 25.01% 1-Year Est. Return
PWA
Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Mirae Asset Global Investments's PYXS Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Pyxis Oncology (PYXS) stake by 13% in Q2 2026, selling an estimated $794 and leaving 2,833 shares worth $8.53K. The position accounts for ﹤0.01% of the portfolio, ranked #1586.

Mirae Asset Global Investments first reported a position in PYXS in Q4 2024 and has held it in 7 quarters since. 7 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • Mirae Asset Global Investments held 2,833 shares of Pyxis Oncology worth $8.53K as of Q2 2026.
  • Mirae Asset Global Investments sold 415 Pyxis Oncology shares in Q2 2026, an estimated $794.
  • Pyxis Oncology made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1586 holding.
  • Mirae Asset Global Investments first reported a position in Pyxis Oncology in Q4 2024 and has held it in 7 quarters since.
  • 7 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.